Napoleone Ferrara and the saga of vascular endothelial growth factor

Endothelium: Journal of Endothelial Cell Research

Volumn 15, Issue 1-2, 2008, Pages 1-8

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; History Of Medicine; Tumor Growth; Vascular Endothelial Growth Factor Vascular Permeability Factor

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; PLACEBO; VASCULOTROPIN;

ANGIOGENESIS; BIOCHEMISTRY; BLEEDING; BONE GROWTH; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM PERFORATION; DRUG DESIGN; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE GLAND; HUMAN; HYPERTENSION; IN VIVO STUDY; INHIBITION KINETICS; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; MOLECULAR CLONING; MONOTHERAPY; NONHUMAN; ORGANOGENESIS; OSSIFICATION; OVARY; PANCREAS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEINURIA; RETINA MACULA AGE RELATED DEGENERATION; SHORT SURVEY; SOLID TUMOR; THROMBOEMBOLISM; TISSUE DISTRIBUTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HISTORY, 20TH CENTURY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 46049117069     PISSN: 10623329     EISSN: 10292373     Source Type: Journal    
DOI: 10.1080/10623320802092377     Document Type: Short Survey

References (56)

1. Aiello, L. P., Avery, R., Arrigg, R., Keyt, B., Jampel, H., Shah, S., Pasquale, L., Thieme, H., Iwamoto, M., Park, J. E., Nguyen, H., Aiello, L. M., Ferrara, N. and King, G. L. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine, 331, pp. 1480-1487.
2. Bogaert, E., Van Damme, P., Van Den Bosch, L. and Robberecht, W. (2006) Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. Muscle Nerve, 34, pp. 391-405.
3. Borgstrom, P., Bourdon, M. A., Hillan, K. J., Sriramarao, P. and Ferrara, N. (1998) Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma microtumors. in vivo. Prostate, 35, pp. 1-10.
4. Borgstrom, P., Gold, D. P., Hillan, K. J. and Ferrara, N. (1999) Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing antibody and doxorubicin. Anticancer Research, 19, pp. 4203-4214.
5. Borgstrom, P., Hillan, K. J., Sriramarao, P. and Ferrara, N. (1996) Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concept of angiostatic therapy from intravital videomicroscopy. Cancer Research, 56, pp. 4032-4039.
6. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyet, S., Kiechens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W. and Nagy, A. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 380, pp. 435-439.
7. Cleaver, O. and Melton, D. A. (2003) Endothelial signaling during development. Nature Medicine, 9, pp. 661-668.
8. Collins, P. D., Connolly, D. T. and Williams, T. J. (1993) Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. British Journal of Pharmacology, 109, pp. 195-199.
9. Connolly, D. T., Heuvelman, D. M., Nelson, R., Olander, J. V., Eppley, B. L., Delfino, J. J., Siegel, N. R., Leimgruber, R. M. and Feder, J. (1989) Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. Journal of Clinical Investigation, 84, pp. 1470-1478.
10. de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N. and Williams, L. T. (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 255, pp. 989-991.
11. Dvorak, H. F., Nagy, J. A., Berse, B., Brown, L. F., Yeo, K. T., Yeo, T. K., Dvorak, A. M., van de Water, L., Sioussat, T. M. and Senger, D. R. (1992) Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Annals New York Academy of Sciences, 667, pp. 101-111.
12. Dvorak, H. F., Orenstein, N. S., Carvalho, A. C., Churchill, W. H., Dvorak, A. M., Galli, S. J., Feder, A. M., Rypysc, J. and Giovinco, F. (1979) Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. Journal of Immunology, 122, pp. 166-174.
13. Esser, S., Wolburg, K., Wolburg, H., Breier, G., Kurzchaliam, T. and Risau, W. (1998) Vascular endothelial growth factor induces endothelial fenestrations in vitro. Journal of Cell Biology, 140, pp. 947-959.
14. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell Braxton, L., Hillan, K. J. and Moore, M. W. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature, 380, pp. 439-442.
15. Ferrara, N., Chen, H., Davis Smyth, T., Gerber, H. P., Nguyen, T. N., Peers, D., Chisholm, V., Hillan, K. J. and Schwall, R. H. (1998) Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Medicine, 4, pp. 336-340.
16. Ferrara, N., Fujii, D. K., Goldsmith, P. C., Widdicombe, J. H. and Weiner, R. I. (1987) Transport epithelial characteristics of cultured bovine pituitary follicular cells. American Journal of Physiology, 252, pp. E304-E312.
17. Ferrara, N., Frantz, G., Le Couter, J., Dillard-Telm, L., Pham, T., Draksharapu, A., Giordano, T. and Peale, F. (2003) Differential expression of the angiogenic factor genes VEGF and EG-VEGF in normal and polycistic human ovaries. American Journal of Pathology, 162, pp. 1881-1893.
18. Ferrara, N. and Henzel, W. J. (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochemical Biophysical Research Communications, 161, pp. 851-858.
19. Gerber, H. P., Condorelli, F., Park, J. and Ferrara, N. (1997) Differential transcriptional regulation of the two VEGF receptor genes. Flt-1, but not Flk-1/KDR is up-regulated by hypoxia. Journal of Biological Chemistry, 272, pp. 23659-23667.
20. Gerber, H. P., Kowalski, J., Sherman, D., Eberhard, D. A. and Ferrara, N. (2000) Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Research, 60, pp. 6253-6258.
21. Gerber, H. P., Vu, T. H., Ryan, A. M., Kowalski, J., Werb, Z. and Ferrara, N. (1999) VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nature Medicine, 5, pp. 623-628.
22. Gerhardt, H., Ruhrberg, C., Abramsson, A., Fujisawa, H., Shima, D. and Betsholtz, C. (2004) Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. Developmental Dynamics, 231, pp. 503-509.
23. Gordon, M. S., Margolin, K., Talpaz, M., Sledge Jr., G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S. and Adelman, D. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. Journal of Clinical Oncology, 19, pp. 843-850.
24. Greenberg, D. A. and Jin, K. (2005) From angiogenesis to neuropathology. Nature, 438, pp. 954-959.
25. Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B. and Leung, D. W. (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Molecular Endocrinology, 5, pp. 1806-1814.
26. Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J. and Ferrara, N. (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. Journal of Biological Chemistry, 267, pp. 26031-26037.
27. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, H., Helm, W., Berlin, J., Griffings, S., Holmgren, R., Ferrara, N., Rogers, B., Ross, R., Baron, A. and Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovarin for metastatic colorectal cancer. New England Journal of Medicine, 350, pp. 2335-2342.
28. Horwitz, H. and Saini, S. (2006) Bevacizumab in the treatment of metastatic colorectal cancer: Safety profile and management of adverse events. Seminars in Oncology, 33, pp. S26-S34.
29. Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Npvotny, W. F., Lieberman, G., Griffing, S. and Bergsland, E. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 21, pp. 60-65.
30. Karkkainen, M. J., Haiko, P., Sainio, K., Partanen, J., Taipale, J., Petrova, T. V., Jeltsch, M., Jackson, D. G., Talikka, M., Rauvala, H., Betsholtz, C. and Alitalo, K. (2004) Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nature Immunology, 5, pp. 74-80.
31. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S. and Ferrara, N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature, 362, pp. 841-844.
32. Kukk, E., Lymboussaki, A., Taira, S., Kaipainen, A., Jeltsch, V., Joukov, V. and Alitalo, K. (1996) VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development, 122, pp. 3829-3837.
33. Jussila, L. and Alitalo, K. (2002) Vascular growth factors and lymph angiogenesis. Physiological Reviews, 8, pp. 673-700.
34. Lambrechts, D. and Carmeliet, P. (2006) VEGF at the neurovascular interface: Therapeutic implications for motor neuron disease. Biochimica Biophysica Acta, 1762, pp. 1109-1121.
35. Lammert, E., Gu, G., Mc Laughlin, M., Brown, D., Brekken, R., Murtaugh, L. C., Gerber, H. P., Ferrara, N. and Melton, D. A. (2003) Role of VEGF-A in vascularization of pancreatic islets. Current Biology, 13, pp. 1070-1074.
36. Le Couter, J., Kowalski, J., Foster, J., Hass, P., Zhang, Z., Dillard-Telm, L., Frants, G., Rangell, L., Deguzman, L., Keller, G. A., Peale, F., Gurney, A., Hillan, K. J. and Ferrara, N. (2001) Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature, 412, pp. 877-884.
37. Le Couter, J., Lin, R. and Ferrara, N. (2002) Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nature Medicine, 8, pp. 913-917.
38. Le Couter, J., Moritz, D. R., Li, B., Phillips, G. L., Liang, X. H., Gerber, H. P., Hillan, K. J. and Ferrara, N. (2003) Angiogenesis-independent endothelial protection of liver: Role of VEGFR-1. Science, 299, pp. 890-893.
39. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. and Ferrara, N. (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 246, pp. 1306-1309.
40. Margolin, K., Gordon, M. S., Holmgren, E., Gaudreault, J., Novotny, W., Fyfe, G., Adelman, D., Stalter, S. and Breed, J. (2001) Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. Journal of Clinical Oncology, 19, pp. 851-856.
41. Mesiano, S., Ferrara, N. and Jaffe, R. B. (1998) Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascite formation by immunoneutralization. American Journal of Pathology, 153, pp. 1249-1256.
42. Meyer, M., Clauss, M., Lepple-Wienhues, A., Waltenberger, J., Augustin, H. G., Ziche, M., Lanz, C., Buttner, M., Rziha, H. J. and Dehio, C. (1999) A novel vascular endothelial growth factor encoded by Orf virsu, VEGF-E, mediated angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO Journal, 18, pp. 363-374.
43. Nagy, J. A., Masse, E. M., Herzberg, K. T., Meyers, M. S., Yeo, K. T., Sioussat, T. M. and Dvorak, H. F. (1995) Pathogenesis of ascites tumor growth. Vascular permeability factor, vascular hyperpermeability and ascites fluid accumulation. Cancer Research, 55, pp. 360-368.
44. Nico, B., Mangieri, D., Benagiamo, V., Crivellato, E. and Ribatti, D. (2007) Nerve growth factor as an angiogenic factor. Microvascular Research, 75, pp. 135-141.
45. Park, J. E., Chen, H. H., Winer, J., Houck, K. A. and Ferrara, N. (1994) Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. Journal of Biological Chemistry, 269, pp. 25646-25654.
46. Phillips, H. S., Hains, J., Leung, D. W. and Ferrara, N. (1990) Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology, 127, pp. 965-967.
47. Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., Krummen, L., Winkler, M. and Ferrara, N. (1997) Humanization of anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Research, 57, pp. 4593-4599.
48. Raab, S. and Plate, K. H. (2007) Different networks, common growth factors: Shared growth factors and receptors of the vascular and the nervous system. Acta Neuropathologica, 113, pp. 607-626.
49. Ravindranath, N., Little-Ihrig, L., Phillips, H. S., Ferrara, N. and Zeleznik, A. J. (1992) Vascular endothelial growth factor messanger ribonucleic acid expression in the primate ovary. Endocrinology, 131, pp. 254-260.
50. Senger, D. R., Connolly, D. T., Van de Water, L., Feder, J. and Dvorak, H. F. (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Research, 50, pp. 1774-1778.
51. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S. and Dvorak, H. F. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 219, pp. 983-985.
52. Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. and Klagsbrun, H. M. (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor to vascular endothelial growth factor. Cell, 92, pp. 735-745.
53. Warren, R. S., Yuan, H., Matli, M. R., Gillett, N. A. and Ferrara, N. (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. Journal of Clinical Investigation, 95, pp. 1789-1797.
54. Whitaker, G. B., Limberg, B. J. and Rosembaum, J. S. (2001) Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). Journal of Biological Chemistry, 276, pp. 25520-25531.
55. Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Tapalian, S. L., Steinberg, S. M., Chen, H. X. and Rosenberg, S. A. (2003) A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. New England Journal of Medicine, 349, pp. 427-434.
56. Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N. and Jain, R. K. (1996) Time-dependent vascular regression and permeability changes in established xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proceedings of the National Academy of Sciences of the United States of America, 93, pp. 14765-14770.